Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.62 |
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | IL1RN | P18510 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216185 | 0.92 | PTPN1 (0.62) | CA2CA1PTPN1PTPN11MAPK1 | |
| SCHEMBL28665290 | 0.90 | PTPN1 (0.60) | CA2CA1PTPN1PTPN11MAPK1 | |
| SCHEMBL1976973 | 0.90 | PTPN1 (0.60) | CA2CA1PTPN1PTPN11MAPK1 | |
| Diphenylamine SCHEMBL1060675 | 0.82 | HSD17B10 (0.52) | CA2CA1MAPK1PTGS1PTGS2 | |
| SCHEMBL19042259 | 0.80 | CA2 (0.49) | CA2CA1PTPN1PTPN11MAPK1 | |
| SCHEMBL17266478 | 0.79 | PTPN1 (0.49) | CA2CA1PTPN1PTPN11MAPK1 | |
| Trifluoromethanesulfonamide SCHEMBL4418171 | 0.79 | CA2 (0.49) | CA2CA1PTGS1PTGS2CA5A | |
| SCHEMBL18048059 | 0.78 | PTPN1 (0.51) | CA2CA1PTPN1PTPN11MAPK1 | |
| SCHEMBL6001500 | 0.77 | PTPN1 (0.86) | CA2PTPN1PTPN11MAPK1SMN1; SMN2 | |
| SCHEMBL28027003 | 0.77 | PTPN1 (0.54) | CA2CA1PTPN1PTPN11MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0919541-B1 | Naphthalene compounds, process for their preparation and their pharmaceutical compositions | SERVIER LAB (FR) | 2005-08-10 | — | — | EP | claimed |
| EP-1038863-B1 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2003-06-04 | — | — | EP | claimed |
| EP-1057826-B1 | Substituted dimeric carboxamide derivatives, method for preparing them, and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-04-16 | — | — | EP | claimed |
| EP-0926145-A1 | Napthalene compounds, method for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-06-30 | — | — | EP | claimed |
| CN-109476664-A | New compound as autotaxin inhibitors and the pharmaceutical composition comprising it | 乐高化学生物科学股份有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-109053723-A | Sulfamide derivative and its medicinal usage | EA制药株式会社 | 2018-12-21 | — | — | CN | disclosed |
| WO-2009152102-A2 | PRO-FLUORESCENT PROBES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-2125755-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis Ag (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| EP-0919541-B1 | Naphthalene compounds, process for their preparation and their pharmaceutical compositions | SERVIER LAB (FR) | 2005-08-10 | — | — | EP | disclosed |
| US-6635650-B2 | Such as N-(2-(7-(2-((8-(2-(acetyl-amino)ethyl)-2-naphthyl) oxy)ethoxy)-1-napthyl)ethyl)acetamide for treating or preventing melatoninergic disorders | LES LABORATOIRES SERVIER (FR) | 2003-10-21 | — | — | US | disclosed |
| US-20020035114-A1 | Substituted dimeric compounds | LESIEUR DANIEL (FR) | 2002-03-21 | — | — | US | disclosed |
| US-6319930-B1 | CONTAINING FUSED AROMATIC CARBO- OR HETEROCYCLIC RINGS AND AMIDE, THIOAMIDE, UREA OR THIOUREA GROUPS; USEFUL IN TREATING OR IN PREVENTING MELATONINERGIC DISORDERS. | ADIR ET COMPAGNIE (FR) | 2001-11-20 | — | — | US | disclosed |
| US-6310074-B1 | TREATING MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-10-30 | — | — | US | disclosed |
| US-6147110-A | MELATONINERGIC AGENTS; SLEEP, EATING, CENTRAL NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS | ADIR ET COMPAGNIE (FR) | 2000-11-14 | — | — | US | disclosed |
| US-6143789-A | ENANTIOMORPHS | ADIR ET COMPAGNIE (FR) | 2000-11-07 | — | — | US | disclosed |
| EP-0926145-A1 | Napthalene compounds, method for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-06-30 | — | — | EP | disclosed |
| EP-0919541-A1 | Naphthalene compounds, process for their preparation and their pharmaceutical compositions | ADIR ET COMPAGNIE (FR) | 1999-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035114-A1 | Substituted dimeric compounds | NR0B2, NR0B1, NR2C2 | CA2 3267/4885CA1 3197/4885PTPN1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.